MDX 2003
Alternative Names: MDX-2003Latest Information Update: 29 Mar 2023
At a glance
- Originator ModeX Therapeutics Inc
- Class Antibodies; Antineoplastics; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Leukaemia; Lymphoma
Most Recent Events
- 14 Mar 2023 Preclinical trials in Leukaemia in USA (Parenteral) (ModeX Therapeutics Inc, March 2023)
- 14 Mar 2023 Preclinical trials in Lymphoma in USA (Parenteral) (ModeX Therapeutics Inc, March 2023)
- 14 Mar 2023 ModeX Therapeutics plans file an IND application for Haematological malignancies in late 2024 (Modex Therapeutics pipeline, March 2023)